prestigious medical journal The Lancet has now published Phase 2 clinical trial results of Bharat Biotech's Covaxin. "Due to the difference in dosing regimens between Phase 1 (two doses given 2 weeks apart) and phase 2 (two doses given 4 weeks apart) trials, neutralisation responses were significantly higher in the phase 2 trial than in the phase 1 trial, said the research paper.from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/3t0GVQ1
0 Comments